Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199934 | 0.85 | TMEM97 (0.52) | SIGMAR1THRBTMEM97MAPTTP53 | |
| SCHEMBL30538010 | 0.85 | TMEM97 (0.52) | SIGMAR1THRBTMEM97MAPTTP53 | |
| SCHEMBL9686018 | 0.82 | SIGMAR1 (0.55) | SIGMAR1MAPTHTR1AHTR2CACHE | |
| SCHEMBL9485398 | 0.81 | SIGMAR1 (0.50) | SIGMAR1THRBMAPTTP53ACHE | |
| SCHEMBL14565129 | 0.80 | CYP19A1 (0.46) | SIGMAR1THRBMAPTTP53HTR1A | |
| SCHEMBL4616475 | 0.79 | MAPT (0.51) | SIGMAR1MAPTTP53HTR1AHTR2C | |
| SCHEMBL4615636 | 0.78 | HTR1A (0.45) | SIGMAR1THRBMAPTTP53HTR1A | |
| SCHEMBL745588 | 0.78 | SIGMAR1 (0.48) | SIGMAR1THRBMAPTTP53HTR1A | |
| SCHEMBL3035789 | 0.78 | BRPF1 (0.47) | SIGMAR1THRBMAPTTP53HTR1A | |
| SCHEMBL8281885 | 0.78 | SIGMAR1 (0.45) | SIGMAR1THRBMAPTTP53HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429274-B2 | Agent and method for the oxidative coloring of keratin fibers | WELLA AG (DE) | 2008-09-30 | — | — | US | claimed |
| EP-1601335-B1 | MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES | WELLA AG (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1699427-B1 | AGENT AND METHOD FOR OXIDATIVELY DYING KERATIN FIBERS | WELLA AG (DE) | 2008-02-27 | — | — | EP | claimed |
| US-7326254-B2 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | WELLA AG (DE) | 2008-02-05 | — | — | US | claimed |
| EP-1599178-B1 | MEANS AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2007-12-19 | — | — | EP | claimed |
| US-7291183-B2 | Agent and method for dyeing keratin fibers | WELLA AG (DE) | 2007-11-06 | — | — | US | claimed |
| US-7244278-B2 | Agent and method for oxidative coloring of keratin fibers | WELLA AG (DE) | 2007-07-17 | — | — | US | claimed |
| US-20070079452-A1 | Agent and method for the oxidative coloring of keratin fibers | Wella GmbH (DE) | 2007-04-12 | — | — | US | claimed |
| US-20070067927-A1 | Agent and method for oxidative coloring of keratin fibers | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2007-03-29 | — | — | US | claimed |
| EP-1599179-B1 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2006-10-11 | — | — | EP | claimed |
| US-20060162096-A1 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2006-07-27 | — | — | US | claimed |
| US-20060010616-A1 | Agent and method for dyeing keratin fibers | Wella GmbH (DE) | 2006-01-19 | — | — | US | claimed |
| EP-1601335-A1 | MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES | Wella Aktiengesellschaft (DE) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078152-A1 | MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES | WELLA AKTIENGESELLSCHAFT (DE) | 2004-09-16 | — | — | WO | claimed |
| US-7429274-B2 | Agent and method for the oxidative coloring of keratin fibers | WELLA AG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-7326254-B2 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | WELLA AG (DE) | 2008-02-05 | — | — | US | disclosed |
| US-7291183-B2 | Agent and method for dyeing keratin fibers | WELLA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060010616-A1 | Agent and method for dyeing keratin fibers | Wella GmbH (DE) | 2006-01-19 | — | — | US | disclosed |
| EP-1607447-A1 | Methods and compositions for dyeing a substrate | Hewlett-Packard Development Company, L.P. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050274274-A1 | Methods and compositions for dying a substrate | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060162096-A1 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | KRT18, GPX4, NOX4 | SIGMAR1 4373/4885THRB 3575/4885TMEM97 4358/4885 |
| US-20070067927-A1 | Agent and method for oxidative coloring of keratin fibers | KRT18, KIT, AOC1 | SIGMAR1 4478/4885THRB 4174/4885TMEM97 4278/4885 |
| US-20070079452-A1 | Agent and method for the oxidative coloring of keratin fibers | KRT18, KIT, CKMT1A; CKMT1B | SIGMAR1 4448/4885THRB 4469/4885TMEM97 4263/4885 |
| US-20060010616-A1 | Agent and method for dyeing keratin fibers | KRT18, KIT, MKI67 | SIGMAR1 3812/4885THRB 4604/4885TMEM97 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.